[
  {
    "ts": null,
    "headline": "Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q4 2025 Update",
    "summary": "Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q4 2025 Update",
    "url": "https://finnhub.io/api/news?id=e6e4798152e96670c0503e9df9c92123ac01373baf6237c77d912a394a502444",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770850555,
      "headline": "Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q4 2025 Update",
      "id": 139052262,
      "image": "",
      "related": "A",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e6e4798152e96670c0503e9df9c92123ac01373baf6237c77d912a394a502444"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Announces Cash Dividend of 25.5 Cents per Share",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026.",
    "url": "https://finnhub.io/api/news?id=8f59576db7d6a37c579911cec12696bdc378ab7de0b4595b732491bb4ca895bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770844500,
      "headline": "Agilent Announces Cash Dividend of 25.5 Cents per Share",
      "id": 139049647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026.",
      "url": "https://finnhub.io/api/news?id=8f59576db7d6a37c579911cec12696bdc378ab7de0b4595b732491bb4ca895bd"
    }
  },
  {
    "ts": null,
    "headline": "Bloomberg's 2026 Watch List Flags 5 Ideal 'Safer' February Dividend Buys",
    "summary": "Bloomberg's 2026 Dividend Focus list highlights 16 'safer' stocks with free cash flow yields exceeding dividend yields. Read full analysis here.",
    "url": "https://finnhub.io/api/news?id=60dfe369b77c08b73e3e6e285bfa9ef30927f10e9c21a68be97c1bef06a0a0b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834834,
      "headline": "Bloomberg's 2026 Watch List Flags 5 Ideal 'Safer' February Dividend Buys",
      "id": 139050330,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/512344182/image_512344182.jpg?io=getty-c-w1536",
      "related": "A",
      "source": "SeekingAlpha",
      "summary": "Bloomberg's 2026 Dividend Focus list highlights 16 'safer' stocks with free cash flow yields exceeding dividend yields. Read full analysis here.",
      "url": "https://finnhub.io/api/news?id=60dfe369b77c08b73e3e6e285bfa9ef30927f10e9c21a68be97c1bef06a0a0b2"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.",
    "url": "https://finnhub.io/api/news?id=fd60b10133ebfa6f180239dd94c15e3c889274fbf43bad059080dc9e2b033cd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770814800,
      "headline": "Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award",
      "id": 139042566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.",
      "url": "https://finnhub.io/api/news?id=fd60b10133ebfa6f180239dd94c15e3c889274fbf43bad059080dc9e2b033cd1"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finnhub.io/api/news?id=c9bdfe3016d669de711536a7380515347459a5ca78c0ae55dc0c7e5529255a11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770810300,
      "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
      "id": 139041046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "SANTA CLARA, Calif., February 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
      "url": "https://finnhub.io/api/news?id=c9bdfe3016d669de711536a7380515347459a5ca78c0ae55dc0c7e5529255a11"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Technologies Says FDA Approves PD-L1 IHC 22C3 pharmDx In Identifying First-Line Patients With Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Carcinoma",
    "summary": "Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has",
    "url": "https://finnhub.io/api/news?id=4eed52bc45e98ec6c944b3010dc04698c11dee957e68753f3efe12457192e4ea",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770796400,
      "headline": "Agilent Technologies Says FDA Approves PD-L1 IHC 22C3 pharmDx In Identifying First-Line Patients With Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Carcinoma",
      "id": 139043035,
      "image": "",
      "related": "A",
      "source": "Benzinga",
      "summary": "Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has",
      "url": "https://finnhub.io/api/news?id=4eed52bc45e98ec6c944b3010dc04698c11dee957e68753f3efe12457192e4ea"
    }
  }
]